BackgroundAtazanavir/ritonavir is recommended as a preferred second-line antiretroviral regimen in children older than 3 months, alternatively to lopinavir/ritonavir. We performed a systematic review
Patients with serum MDA higher than 2.27 nmol/mL (n = 23) presented higher 30-day mortality (Hazard ratio = 2.9; 95% CI = 1.31–6.33; p = 0.005) than patients with lower levels (n = 27) in the survival
